Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Inclusion Criteria:

* Patient must be less than 70 years old
* Patients with advanced Multiple Myeloma that meet the eligibility requirements for mobilization/debulking with Cytoxan/VP-16/G-CSF, Cytoxan/Taxol/G-CSF, or Cytoxan/G-CSF (according to protocol 506.03); if clinically indicated a lower dose of cytoxan than 4g/m2 may be used for mobilization based on the attending's discretion; also, if the patients had previously collected PBSC of sufficient number in the past and meet the other eligibility requirements, they may be entered on this study after approval by the PI
* Patients with advanced Multiple Myeloma that have an identical syngeneic twin for donation of PBSCs
* Patients have advanced Multiple Myeloma if they were diagnosed initially with stage II or III disease or had stage I disease that progressed after initial therapy or failed to respond to therapy
* Syngeneic Donor Inclusion:

  * Donor and patient have adequate documentation that donor and recipient are syngeneic; including ABO typing, HLA typing and VNTR studies
  * Donor \> 20 kg
  * Donor meets eligibility to donate according to Standard Practice Guidelines

Exclusion Criteria:

* Patient's age \>= 70
* Karnofsky score less than 80
* A left ventricular ejection fraction less than 50%; Patients with congestive heart disease, history of myocardial infarction (MI), coronary artery disease or any arrhythmia history
* Total bilirubin \> 1.5 mg/ml (unless history of Gilbert's disease)
* Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) \> 2 x upper limit of normal
* Estimated creatinine clearance \< 60 ml/min or creatinine serum \> 2.0 mg/dl
* Pregnancy
* Seropositivity for human immunodeficiency virus
* Patients who cannot give informed consent
* Secondary malignancies other than basal cell carcinoma of the skin or carcinoma in situ within the last five years
* History of seizures or requirement for medicines, such as haldol, for controlling mental disorders
* Concurrent need for corticosteroid therapy
* Active connective tissue disease
* Pleural effusion, pericardial effusion or ascites
* Patients allergic to gentamicin
* Patients with positive PCR for hepatitis C or hepatitis B
* Patients with hypersensitivity to E. coli - derived preparations
* Patients with systemic infection at time of IL2 therapy
* Patients who previously have had more than 50% of their pelvic area irradiated
* Patients with pulmonary function tests that show diffusion capacity (corrected) \< 60%, and/or forced expiratory volume in 1 second (FEV1) \< 65% of predicted